Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 717
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Qing, T., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 580
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
Chalabi, M., Verschoor, Y. L., Tan, P. B., Balduzzi, S., van Lent, A. U., Grootscholten, C., Dokter, S., Büller, N. V. J. A., Grotenhuis, B. A., Kuhlmann, K. F. D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400634 · Cited by 541
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12516 · Cited by 470
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M. A., Chang, G. J., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Garrido‐Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 433
Self-citation
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 372
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
André, T., Elez, E., Van Cutsem, E., Jensen, L. H., Bennouna, J., Mendez, G., Schenker, M., de la Fouchardiere, C., Limon, M. L., Yoshino, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402141 · Cited by 286
Self-citation
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 297
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial
André, T., Elez, E., Lenz, H.-J., Jensen, L. H., Touchefeu, Y., Van Cutsem, E., Garcia-Carbonero, R., Tougeron, D., Mendez, G. A., Schenker, M., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02848-4 · Cited by 256
Self-citation
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
Ludford, K. T., Ho, W. J., Thomas, J. V., Raghav, K. P. S., Blum-Murphy, M. A., Fleming, N. D., Lee, M. S., Smaglo, B. G., You, Y. N., Tillman, M. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01351 · Cited by 221
Self-citation
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
Wang, F., Jin, Y., Wang, M., Luo, H., Fang, W. J., Wang, Y., Chen, Y., Huang, R.-J., Guan, W., Li, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02813-1 · Cited by 197
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade
Jin, Z., & Sinicrope, F. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02691 · Cited by 171
Colorectal cancer immunotherapy-Recent progress and future directions
Zhao, W., Jin, L., Chen, P., Li, D., Gao, W., & Dong, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215816 · Cited by 159
Clinical Updates for Colon Cancer Care in 2022
Fabregas, J. C., Ramnaraign, B. H., & George, T. J. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.05.006 · Cited by 159
Predictive biomarkers of colon cancer immunotherapy: Present and future
Hou, W., Cheng, Y., & Zhu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032314 · Cited by 151
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 151
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A. M., & Meric‐Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 145
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 139
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
Self-citation
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 137
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Baltgalvis, K. A., Lamb, K. N., Symons, K. T., Wu, C.-C., Hoffman, M. A., Snead, A. N., Song, X., Glaza, T., Kikuchi, S., Green, J. C., et al. (2024) · Nature · doi:10.1038/s41586-024-07318-y · Cited by 134
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Stage IV Colorectal Cancer Management and Treatment
Dominguez, O. H., Yılmaz, S., & Steele, S. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052072 · Cited by 126
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
Verheijden, R. J., de Groot, J. S., Fabriek, B. O., Hew, M. N., May, A. M., & Suijkerbuijk, K. P. M. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00191 · Cited by 122
Optimizing immunotherapy for colorectal cancer
Ganesh, K. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00569-4 · Cited by 120
Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Shah, D., Soper, B. W., & Shopland, L. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190379 · Cited by 118
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy
Fakih, M., Sandhu, J. S., Lim, D. W., Li, X., Li, S., & Wang, C. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7845 · Cited by 122
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 116
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 112
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 106
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Le, D. T., Diaz, L. A., Kim, T. W., Cutsem, E. V., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B. H., Kavan, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.016 · Cited by 100
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
Chen, Y., Zheng, X., & Wu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.792691 · Cited by 104
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 102
Self-citation
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Williams, C. J. M., Peddle, A. M., Kasi, P. M., Seligmann, J. F., Roxburgh, C. S. D., Middleton, G., & Tejpar, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00943-6 · Cited by 99
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
Güven, D. C., Kavgacı, G., Erul, E., Syed, M. P., Magge, T., Saeed, A., Yalçın, Ş., & Şahin, İ. H. (2024) · The Oncologist · doi:10.1093/oncolo/oyae013 · Cited by 99
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Ambrosini, M., Manca, P., Nasca, V., Sciortino, C., Ghelardi, F., Seligmann, J. F., Taı̈eb, J., & Pietrantonio, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01015-z · Cited by 94
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 88
Mechanism and strategies of immunotherapy resistance in colorectal cancer
Shan, J., Han, D. H., Shen, C., Lei, Q., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016646 · Cited by 85
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
Chen, E. X., Loree, J. M., Titmuss, E., Jonker, D. J., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.46094 · Cited by 85
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Hereditary cancer syndromes
Имянитов, Е. Н., Kuligina, E. S., Соколенко, А. П., Suspitsin, E. N., Yanus, G. A., Iyevleva, A. G., Ivantsov, A. O., & Алексахина, С. Н. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i2.40 · Cited by 82
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Lenz, H., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Élez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008409 · Cited by 83
Self-citation
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Yan, S., Wang, W., Feng, Z., Xue, J., Liang, W., Wu, X., Tan, Z., Zhang, X., Zhang, S., Li, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403533 · Cited by 83
A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors
Cai, L., Chen, A., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13785 · Cited by 73
Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Hegewisch‐Becker, S., Mendez, G. A., Chao, J., Němeček, R., Feeney, K., Cutsem, E. V., Al‐Batran, S., Mansoor, W., Maisey, N. R., Pazo-Cid, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01636 · Cited by 68
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 65
Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
Zhu, J., Lian, J., Xu, B., Pang, X., Ji, S., Zhao, Y., & Lu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120684 · Cited by 65
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Manca, P., Corti, F., Intini, R., Mazzoli, G., Miceli, R., Germani, M. M., Bergamo, F., Ambrosini, M., Cristarella, E., Cerantola, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.029 · Cited by 69
Self-citation
Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022
André, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 63
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis
Takenaka, Y., Oya, R., Takemoto, N., & Inohara, H. (2022) · Head & Neck · doi:10.1002/hed.26997 · Cited by 64
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
Overman, M. J., Gelsomino, F., Aglietta, M., Wong, M. K., Mirón, M. L. L., Leonard, G., Alfonso, P. G., Hill, A. G., Gracián, A. C., Cutsem, E. V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008689 · Cited by 63
Self-citation
Radioimmunotherapy in colorectal cancer treatment: present and future
Shi, J., Sun, Z., Gao, Z., Huang, D., Hong, H., & Gu, J. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105180 · Cited by 60
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
Jiang, M., Hu, Y., Lin, G., & Chen, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906251 · Cited by 59
Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective
Büchler, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888181 · Cited by 55
Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer
Emiloju, O. E., & Sinicrope, F. A. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3323 · Cited by 56
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers
Amato, M., Franco, R., Facchini, G., Addeo, R., Ciardiello, F., Berretta, M., Vita, G., Sgambato, A., Pignata, S., Caraglia, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158726 · Cited by 57
Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
Saberzadeh-Ardestani, B., Jones, J. C., Hubbard, J. M., McWilliams, R. R., Halfdanarson, T. R., Shi, Q., Sonbol, M. B., Ticku, J., Jin, Z., & Sinicrope, F. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0400 · Cited by 55
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 52
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
Ros, J., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Cancers · doi:10.3390/cancers15174245 · Cited by 53
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 54
Updated Management of Colorectal Cancer Liver Metastases: Scientific Advances Driving Modern Therapeutic Innovations
Patel, R. K., Rahman, S., Schwantes, I. R., Bartlett, A. Q., Eil, R. L., Farsad, K., Fowler, K. J., Goodyear, S. M., Hansen, L., Kardosh, A., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.012 · Cited by 55
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Sangro, B., Galle, P. R., Kelley, R. K., Charoentum, C., Toni, E. N. D., Ostapenko, Y., Heo, J., Cheng, A., Woods, A. W., Gupta, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01462 · Cited by 51
Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy
Kavun, A., Veselovsky, E., Lebedeva, A., Belova, E., Kuznetsova, O. A., Yakushina, V. D., Grigoreva, T. V., Mileyko, V., Fedyanin, M. Y., & Ivanov, M. V. (2023) · Cancers · doi:10.3390/cancers15082288 · Cited by 52
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 51
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
Moretto, R., Rossini, D., Catteau, A., Antoniotti, C., Giordano, M., Boccaccino, A., Ugolini, C., Proietti, A., Conca, V., Kassambara, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006633 · Cited by 46
Self-citation
Honokiol‐Magnolol‐Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti‐PD‐1 Immunotherapy in Colorectal Cancer by Triggering GSDME‐Dependent Pyroptosis
Gao, Q., Sheng, Q., Yang, Z., Zhu, Z., Li, L., Xu, L., Xia, J., Qiao, Y., Gu, J., Zhu, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202417022 · Cited by 45
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
Frentzas, S., Gan, H. K., Cosman, R., Coward, J. I. G., Tran, B., Millward, M., Zhou, Y., Wang, W., Xia, D., Wang, Z. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101242 · Cited by 46
Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
Zhang, X., Yang, R., Wu, T., Cai, X., Li, G., Yu, K., Li, Y., Ding, R., Dong, C., Li, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.913483 · Cited by 44
Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
Li, A., & Fang, J. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230025 · Cited by 46
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
Advancing translational research for colorectal immuno-oncology
Thomas, E., Wright, J. A., Blake, S. J., Page, A. J., Worthley, D. L., & Woods, S. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02392-x · Cited by 44
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
Merhi, M., Ahmad, F., Taib, N., Inchakalody, V. P., Shahab Uddin, M. S., Shablak, A., & Dermime, S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.001 · Cited by 41
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Bhamidipati, D., & Subbiah, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.002 · Cited by 45
Metastasis organotropism in colorectal cancer: advancing toward innovative therapies
He, K., Wang, Z., Luo, M., Li, B., Ding, N., Li, L., He, B., Wang, H., Cao, J., Huang, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04460-5 · Cited by 45
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors
Wu, Z., Wu, Q., Han, Y., Xiang, S.-J., Wang, Y., Wu, W.-W., Chen, Y., Feng, Z., Wang, Y.-Y., Xu, Z.-G., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.002 · Cited by 46
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
Koustas, E., Trifylli, E.-M., Sarantis, P., Papadopoulos, N., Karapedi, E., Aloizos, G., Damaskos, C., Garmpis, N., Garmpi, A., Papavassiliou, K. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126664 · Cited by 43
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
Nádorvári, M. L., Lotz, G., Kulka, J., Kiss, A., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611719 · Cited by 40
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
DNA mismatch repair in cancer immunotherapy
Guan, J., & Li, G. (2023) · NAR Cancer · doi:10.1093/narcan/zcad031 · Cited by 41
Ensemble transformer-based multiple instance learning to predict pathological subtypes and tumor mutational burden from histopathological whole slide images of endometrial and colorectal cancer
Wang, C., Liu, T.-C., Lai, P.-J., Muzakky, H., Wang, Y., Yu, M.-H., Wu, C.-H., & Chao, T. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103372 · Cited by 41
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota
Rahimi, A. R., Baghernejadan, Z., Hazrati, A., Malekpour, K., Samimi, L. N., Najafi, A., Falak, R., & Khorramdelazad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118014 · Cited by 41
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives
Manzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 41

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks